Thursday, April 2, 2020

James Lipton Dies from Bladder Cancer at the Age Of 93

James Lipton, dean emeritus of the Actors Studio Drama School has passed away after battling bladder cancer at the age of 93. He was a scriptwriter, author, lyricist, producer, choreographer, and academic. He served the Inside the Actors Studio since 1994, which grants Master of Fine Arts degrees in acting, directing, and playwriting.

Omega-3 Supplements Offer No Protection against Cancer, Finds Study

A new study, which was funded by the World Health Organization (WHO), has found that fish oil or omega-3 fatty acid supplements offer “little to no” protection against cancer. Researchers from the University of Anglia has found that the billion-dollar industry of supplements offer no health benefits as they claim.

FDA Approves NDA for Neratinib Along With Capecitabine for Metastatic Breast Cancer

The FDA announced the approval of a supplemental new drug application (sNDA) of neratinib in combination with capecitabine for the treatment of advanced breast cancer. Neratinib, developed by Puma Biotechnology, announced the FDA approval for its drug for metastatic breast cancer.

Portable ‘Electronic Nose’ Device Could Detect Esophageal Cancer

A new study has found that a portable and highly sensitive electronic nose device could help predict the presence of esophageal cancer, aka Barrett’s esophagus. The device analyzes the difference in volatile organic compounds (VOCs) through a person’s breathing, predicting esophageal cancer.

Weight Loss Pill Belviq (Lorcaserin) Recalled Due To Potential Cancer Risk

Weight loss pills Belviq (lorcaserin) has been withdrawn from the US market after a clinical trial of the drug found that it potentially increased the risk of cancer. The FDA said more than 7 percent of patients who took the drug reported the diagnosis of 520 primary cancers.

People with More Than 10 Sexual Partners Vulnerable To Cancer

A new study has found that people with more than 10 lifetime sexual partners are at increased risk of any form of cancer. The risk was more in women than men. Although the exact reason behind the association is unclear, researchers said it could be due to sexually transmitted infections, such as HPV.

Keytruda Found Effective In yet another Cancer Indication

Merck & Co. has announced the clinical trial results of its drug Keytruda, stating that it has been found effective in treating triple-negative breast cancer (TNBC) when given along with chemotherapy. The company said Keytruda, along with chemotherapy, could improve the survival chance in women with TNBC.